Interaction of dexloxiglumide, a cholecystokinin type-1 receptor antagonist, with human cytochromes P450

Biopharmaceutics and Drug Disposition

Volumn 25, Issue 4, 2004, Pages 163-176

  Hall, Michael ^a   Persiani, Stefano ^b   Cheung, Yen Ling ^a   Matthews, Anne ^a   Cybulski, Richard ^a   Holding, Jeremy D ^a   Kapil, Ram ^c   D'Amato, Massimo ^b   Makovec, Francesco ^b   Rovati, Lucio C ^b  

^a Huntington Life Sciences Ltd   (United Kingdom)

^b Rotta Research Laboratorium   (Italy)

^c FOREST RESEARCH INSTITUTE   (United States)

Author keywords

CYP2C9; Cytochromes P450; Dexloxiglumide; Drug interactions

Indexed keywords

CARBON 14; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DEXLOXIGLUMIDE; ENZYME INHIBITOR; LAURIC ACID; OXYGENASE; TOLBUTAMIDE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SPECIFICITY; ENZYME SUBSTRATE; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; ISOTOPE LABELING; LIVER MICROSOME; MALE; PREDICTION;

ARYL HYDROCARBON HYDROXYLASES; CELLS, CULTURED; CYTOCHROME P-450 CYP2E1; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MICROSOMES, LIVER; PENTANOIC ACIDS; RECEPTORS, CHOLECYSTOKININ;

EID: 2942637496     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.397     Document Type: Article

References (40)

1. Ito K, Iwatsubo T, Kanamitsu S, Ueda K, Suzuki H, Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol Rev 1998; 50: 387-411.
2. Lin JH, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998; 35: 361-390.
3. Greenblatt DJ, von Moltke LL. Drug-drug interactions: clinical perspective. In Drug-Drug Interactions, Rodrigues AD (ed.). Marcel Dekker: New York, Basel, 2002; 565-584.
4. Nelson DR, Koymans L, Kamataki T, et al. P450 super-family: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42.
5. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997; 32: 210-258.
6. Yao C, Levy RH. Inhibition-based metabolic drug-drug interactions: predictions from in vitro data. J Pharm Sci 2002; 91: 1923-1935.
7. Woodruff GN, Hughes J. Cholecystokinin antagonists. Annu Rev Pharmacol Toxicol 1991; 31: 469-501.
8. A-receptors in gastrointestinal disorders. In Drug Development: Molecular Targets for GI Diseases, Gaginell TS, Guglietta A (eds). Humana Press: Totowa, NJ, 1999; 147-175.
9. Grider JR. Role of cholecystokinin in the regulation of gastrointestinal motility. J Nutr 1994; 124 (Suppl 8): 1334S-1339S.
10. Fioramonti J, D'Amato M, Rovati L, Buéno L. Effects of dexloxiglumide on gastric emptying delayed by colonic distension in dogs. Neurogastroent Motil 1996; 8: 172.
11. Rouzade ML, Fioramonti J, D'Amato, M, Rovati L, Buéno L. Inhibitory action of dexloxiglumide on transient lower oesophageal sphincter relaxation in dogs. Neurogastroent Motil 1996; 8: 188.
12. Meier R, Beglinger C, Giacovelli G, D'Amato M. Effect of the CCK-A receptor antagonist dexloxiglumide on postprandial gallbladder emptying and colonic transit time in healthy volunteers. Gastroenterology 1997; 112: A788.
13. A-receptor antagonist dexloxiglumide in IBS. Gut 1999; 45 (Suppl V): A258.
14. 1-receptor antagonist dexloxiglumide is effective and safe in female patients with constipation predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: S317.
15. Feinle C, Meier O, D'Amato, M. CCK-A Receptor blockade improves dyspeptic symptoms due to duodenal lipid and gastric distension in functional dyspepsia. Gastroenterology 1999; 116 (Suppl): A992.
16. A) receptor antagonist treatment of irritable bowel syndrome. Drug Future 1999; 24: 725-728.
17. Scarpignato C, Kisfalvi I, D'Amato M, Varga G. Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Aliment Pharm Therap 1996; 10: 411-419.
18. Persiani S, D'Amato M, Makovec F, Tavares IA, Bishai PM, Rovati LC. Pharmacokinetics of dexIoxiglumide after administration of single and repeat oral escalating doses in healthy young males. Int J Clin Pharmacol Ther 2002; 40: 198-206.
19. Webber C, Roth A, Persiani S, et al. Pharmacokinetics and metabolism of the cholecystokinin antagonist dexloxiglumide in male human subjects. Xenobiotica 2003; 33: 625-641.
20. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-275.
21. Rutten AAJJL, Falke HE, Catsburg JF, et al. Interlaboratory comparison of total cytochrome P-450 and protein determinations in rat liver microsomes. Reinvestigation of assay conditions. Arch Toxicol 1987; 61: 27-33.
22. Burke MD, Prough RA, Mayer RT. Characteristics of a microsomal cytochrome P-448-mediated reaction. Ethoxyresorufin O-de-ethylation. Drug Metab Dispos 1977; 5: 1-8.
23. Maurice M, Emiliani S, Dalet-Beluche I, Derancourt J, Lange R. Isolation and characterization of a cytochrome P450 of the IIA subfamily from human liver microsomes. Eur J Biochem 1991; 200: 511-517.
24. Chauret N, Gauthier A, Martin J, Nicoll-Griffith DA. In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat, and horse. Drug Metab Dispos 1997; 25: 1130-1136.
25. Miners JO, Smith KJ, Robson RA, McManus ME, Veronese ME, Birkett DJ. Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. Biochem Pharmacol 1988; 37: 1137-1144.
26. Kronbach T, Mathys D, Gut J, Catin T, Meyer UA. High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver. Anal Biochem 1987; 162: 24-32.
27. Parker GL, Orton TC. Induction by oxyisobutyrates of hepatic and kidney microsomal cytochrome P-450 with specificity towards hydroxylation of fatty acids. In Biochemistry, Biophysics and Regulation of Cytochrome P-450, Gustafsson JA, Carlstedt-Duke J, Mode A, Rafter J (eds). Elsevier/North-Holland Biomedical Press: Amsterdam, 1980; 373-377.
28. Arlotto MP, Trant JM, Estabrook RW. Measurement of steroid hydroxylation reactions by high-performance liquid chromatography as indicator of P450 identity and function. Methods Enzymol 1991; 206: 454-462.
29. Waxman DJ. P450-catalyzed steroid hydroxylation: assay and product identification by thin-layer chromatography. Methods Enzymol 1991; 206: 462-476.
30. Sonderfan AJ, Arlotto MP, Dutton DR, McMillen SK, Parkinson A. Regulation of testosterone hydroxylation by rat liver microsomal cytochrome P-450. Arch Biochem Biophys 1987; 255: 27-41.
31. Tucker GT, Houston JB, Huang SM. EUFEPS conference report. Optimising drug development: strategies to assess drug metabolism/transporter interaction potential-towards a consensus. European Federation of Pharmaceutical Sciences. Eur J Pharm Sci 2001; 13: 417-428.
32. Madan A, Usuki E, Burton LA, Ogilvie BW, Parkinson A. In vitro approaches for studying the inhibition of drug-metabolizing enzymes and identifying the drug-metabolizing enzymes responsible for the metabolism of drugs. In Drug-Drug Interactions, Rodrigues AD (ed). Marcel Dekker: New York, Basel, 2002; 217-294.
33. Cortés A, Cascante M, Cárdenas ML, Cornish-Bowden A. Relationships between inhibition constants, inhibitor concentrations for 50% inhibition and types of inhibition: new ways of analysing data. Biochem J 2001; 357: 263-268.
34. Clarke SE, Jones BC. Human cytochromes P450 and their role in metabolism-based drug-drug interactions. In Drug-Drug Interactions, Rodrigues AD (ed). Marcel Dekker: New York, Basel, 2002; 55-88.
35. Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, Watkins PB. The human CYP3A subfamily: practical considerations. Drug Metab Rev 2000; 32: 339-361.
36. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525-538.
37. Rodrigues AD. Integrated cytochrome P450 reaction phenotyping. Attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 1999; 57: 465-480.
38. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 2003; 43: 443-469.
39. Guo Z, Raeissi S, White RB, Stevens JC. Orphenadrine and methimazole inhibit multiple cytochrome P450 enzymes in human liver microsomes. Drug Metab Dispos 1997; 25: 390-393.
40. Lee CR, Goldstein JA, Pieper JA. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 2002; 12: 251-263.